Molecular Partners AG appointed of Dr. Andreas Harstrick as Chief Medical Officer (CMO) and new member of the Executive Management Team. Dr. Andreas Harstrick will assume the role as CMO starting May 1, 2015 and in his position he will oversee Molecular Partner's clinical activities and expand the clinical development team. Andreas has worked for Imclone Systems, Branchburg NJ, where since 2012 he held the position as SVP Medical Sciences and was a member of the Lilly Oncology Program Review Board and Lilly Oncology Business Development Committee.